Table 2. Inducers of ferroptosis in diverse tumor cells.
| Inducers | Tumor Types | Inhibitors | Decrease Drugs Resistant | Refs. |
|---|---|---|---|---|
| erastin | AML(HL-60 cells) | ferrostatin-1/necrostatin-1 c | cytarabine/ara-C and doxorubicin/adriamycin | [9] |
| erastin | GC cells | Suppression of CDO1 | N/A | [7] |
| Erasin or SASP | GC cells | cisplatin | [50] | |
| dm-Erastin | Pancreatic cancer patient-derived xenograft | N/A | N/A | [51] |
| erastin | Wt EGFR nsclc cells | N/A | Cisplatin | [52] |
| Erastin and SASP | HNC cells | N/A | Cisplatin | [53] |
| erastin | GBM cells | N/A | TMZ | [54] |
| erastin | RMS13 cells | Ferrostatin-1 | PI103 | [55] |
| sorafenib | HCC cells | ferrostatin-1 | N/A | [56] |
| sorafenib | HCC, kidney cancer, melanoma, lung carcinoma, pancreatic adenocarcinoma and colon carcinoma cells | N/A | N/A | [57] |
| sorafenib | HCC cells | N/A | N/A | [59, 60-62] |
| SASP | lymphoma cells | N/A | N/A | [63, 64] |
| Artemisinin derivatives | 60 tumor cell lines | N/A | N/A | [65] |
| ART | ovarian cancer cells,PDAC cell | ferrostatin-1 | N/A | [66] |
| RSL3 | DLBCL cells | ferrostatin-1 | N/A | [68] |